NVAX Novavax Inc
Company Analysis
Latest News
🟢 Novavax is trading 5.3% up today after XFG-adapted Nuvaxovid approvals in U.S., EU and Japan
Novavax is trading 5.3% up at $9.87 after partners received approvals for XFG-adapted Nuvaxovid in the United States, European Union, and Japan for the...
🟢 Novavax is trading 6.26% up today after Nuvaxovid approvals in U.S., EU and Japan
Novavax is trading at $9.84, up +6.26%, after partners received approvals for its XFG-adapted Nuvaxovid vaccine in the United States, European Union, and Japan...
Novavax Wins FDA Approval for COVID Vaccine, Offering mRNA Alternative
The FDA approved Novavax’s updated protein-based COVID-19 vaccine for the 2026-2027 immunization season. The shot provides a non-mRNA alternative to vaccines...
🟢 Novavax rises 5.5% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Novavax is trading 5.52% down today with no clear catalyst identified
Novavax is trading 5.52% down now at $8.45, with no clear company-specific catalyst identified. • No clear company-specific announcement, filing, analyst...
🟢 Novavax is trading 7% up today with no clear catalyst identified
Novavax is trading at $9.01, up +7.01%, with no clear company-specific announcement, filing, analyst action, or regulatory catalyst identified for August 21,...
🔴 Novavax falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Novavax is trading 10% up today after Moderna’s positive Phase 3 melanoma vaccine results
Novavax is trading at $8.73, up 10.15% on August 19, 2026, alongside a broad biotech rally following Moderna’s positive Phase 3 melanoma vaccine results with...
🟢 Novavax rises 6.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Novavax is trading 5.93% up in pre-market with no clear company-specific catalyst
Novavax is trading 5.93% up in pre-market at $8.40, with no new company-specific announcement found to clearly explain the increase. - August 18 close:...
Novavax beats second quarter 2026 estimates and raises full-year revenue guidance amid its strategic shift.
Novavax reported second quarter revenue of $57 million and a net loss of $0.32 per share, beating analyst expectations for both metrics. The results reflect...
🟢 Novavax is trading 5.8% up today ahead of its Q2 earnings report
Novavax is trading at $8.15 (+5.84%) in pre-market as investors position ahead of its August 06, 2026 earnings report. • Analysts expect Q2 2026 revenue of...
Novavax Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
For the second quarter of 2026, analysts expect Novavax to report a consensus revenue of $52.06 million and an EPS loss of $0.38, with shares currently trading...
🔴 Novavax is trading 5.3% down today amid biotech sector profit-taking
Novavax is trading 5.3% down today at $8.44 amid continued profit-taking and broader weakness across high-beta biotech names. • The stock is extending a...
🔴 Novavax is trading 5.1% down today amid biotech sector weakness and macro pressure
Novavax is trading 5.1% down today at $8.86 amid a broader pullback in biotech and risk assets. • Biotech ETFs are off more than 2% as investors continue...
🟢 NVAX is trading 5.5% up today amid ongoing post-earnings strength
NVAX is trading 5.5% up now at $9.98, extending a multi-day rally from the high-$8 range to mid-$9s. The move follows the company’s Q1 2026 earnings beat and...
🟢 NVAX is trading 5.5% up today amid broader market strength and healthcare sector gains
NVAX is trading at $9.37 (+5.46%) amid a broader risk-on tone in the market, with major U.S. indices and healthcare stocks among the day’s top performers. •...
🔴 NVAX trading 5% down after shareholder backlash at AGM
• NVAX is trading at $8.46 (5% down) following public criticism from its largest shareholder, Shah Capital, after the Annual General Meeting (AGM). • The...
🟢 NVAX is trading 5.7% up today after shareholders approve key proposals at annual meeting
NVAX is trading 5.7% up at $9.51, bouncing from recent softness. This comes as Novavax shareholders approved several key proposals at their annual meeting, the...
🟢 Novavax Inc is trading 5.5% up today on continued momentum and technical strength
Novavax Inc is trading at $9.71 (up 5.5%) on June 17, 2026, extending its recent rally as the stock maintains strong technical momentum following its 2025...